Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) EBITDA (2016 - 2025)

Historic EBITDA for Jaguar Health (JAGX) over the last 11 years, with Q3 2025 value amounting to -$7.2 million.

  • Jaguar Health's EBITDA rose 33.05% to -$7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.8 million, marking a year-over-year decrease of 857.4%. This contributed to the annual value of -$30.8 million for FY2024, which is 1009.01% up from last year.
  • Jaguar Health's EBITDA amounted to -$7.2 million in Q3 2025, which was up 33.05% from -$8.0 million recorded in Q2 2025.
  • In the past 5 years, Jaguar Health's EBITDA ranged from a high of -$6.3 million in Q4 2022 and a low of -$11.8 million during Q1 2022
  • Over the past 5 years, Jaguar Health's median EBITDA value was -$8.2 million (recorded in 2024), while the average stood at -$8.7 million.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 10944.46% in 2021, then surged by 4405.01% in 2022.
  • Quarter analysis of 5 years shows Jaguar Health's EBITDA stood at -$10.8 million in 2021, then surged by 41.91% to -$6.3 million in 2022, then decreased by 20.22% to -$7.6 million in 2023, then fell by 7.94% to -$8.2 million in 2024, then increased by 11.27% to -$7.2 million in 2025.
  • Its last three reported values are -$7.2 million in Q3 2025, -$8.0 million for Q2 2025, and -$9.4 million during Q1 2025.